Skip to main content

Table 1 Baseline characteristics of different TyG-BMI groups

From: Triglyceride glucose-body mass index and cardiovascular mortality in patients undergoing peritoneal dialysis: a retrospective cohort study

Characteristics

Total

(n = 2,335)

Quartiles of TyG-BMI

P value

Q1 (n = 584)

< 165.5

Q2 (n = 584)

165.5-<183.7

Q3 (n = 584)

183.7-<209.2

Q4 (n = 583)

> 209.2

Age (years)

46.1 ± 14.8

40.4 ± 15.1

45.2 ± 15.1

46.7 ± 13.8

50.2 ± 13.3

< 0.001*

Male sex (n, %)

1382 (59.2)

296 (50.7)

357 (61.1)

376 (64.4)

353 (60.5)

< 0.001*

Dialysis duration (months)

46.6 (22.4–78.0)

48.8 (21.8–89.0)

46.0 (21.6–76.2)

47.9 (24.4–75.3)

43.5 (21.9–70.7)

0.076

Primary renal diseases

      

Glomerulonephritis (n, %)

1432 (61.3)

461 (78.9)

395 (67.6)

325 (55.7)

251 (43.1)

< 0.001*

Diabetic nephropathy (n, %)

480 (20.6)

33 (5.7)

78 (13.4)

143 (24.5)

226 (38.8)

< 0.001*

Renal vascular diseases (n, %)

179 (7.7)

23 (3.9)

43 (7.4)

51 (8.7)

62 (10.6)

< 0.001*

Others (n, %)

244 (10.4)

67 (11.5)

68 (11.6)

65 (11.1)

44 (7.5)

0.069

BMI (kg/m2)

21.8 ± 3.2

18.4 ± 1.5

20.5 ± 1.3

22.5 ± 1.4

25.6 ± 2.6

< 0.001*

Systolic pressure (mmHg)

136 ± 20

135 ± 19

137 ± 20

136 ± 20

136 ± 21

0.617

Diastolic pressure (mmHg)

85 ± 14

87 ± 13

86 ± 14

84 ± 14

83 ± 13

< 0.001*

Urine output (ml)

1000 (600–1500)

900 (500–1400)

1000 (600–1500)

1000 (700–1600)

1100 (600–1700)

< 0.001*

Comorbidities

      

Diabetes (n, %)

564 (24.2)

41 (7.0)

96 (16.4)

170 (29.1)

257 (44.1)

< 0.001*

CVD history (n, %)

782 (33.5)

136 (23.3)

181 (31.0)

213 (36.5)

252 (43.2)

< 0.001*

Hypertension (n, %)

664 (28.4)

79 (13.5)

155 (26.5)

188 (32.2)

242 (41.5)

< 0.001*

Laboratory parameters

      

Hemoglobin (g/l)

101 ± 22

101 ± 24

101 ± 22

101 ± 22

101 ± 20

0.900

Albumin (g/l)

36.1 ± 5.1

36.9 ± 5.3

36.7 ± 4.9

36.5 ± 5.1

36.6 ± 5.1

0.593

Triglyceride (mg/dl)

124 (89–178)

91 (68–122)

116 (89–156)

130 (98–172)

186 (134–274)

< 0.001*

FBG (mg/dl)

84.6 (75.6–100.8)

79.2 (70.2–86.4)

84.6 (75.6–95.4)

88.2 (77.4–104.4)

95.4 (82.8–138.6)

< 0.001*

TyG index

8.62 (8.23–9.08)

8.17 (7.88–8.49)

8.54 (8.23–8.85)

8.69 (8.38–9.04)

9.20 (8.78–9.65)

< 0.001*

Total cholesterol (mg/dl)

193 ± 52

185 ± 49

192 ± 50

196 ± 50

202 ± 55

< 0.001*

HDL-C (mg/dl)

47.5 ± 16.3

54.4 ± 18.2

49.2 ± 16.5

45.7 ± 13.5

40.8 ± 13.2

< 0.001*

LDL-C (mg/dl)

114 ± 39

108 ± 35

115 ± 37

119 ± 39

116 ± 42

< 0.001*

Serum creatinine (mg/dl)

8.74 ± 3.10

8.82 ± 3.14

8.84 ± 3.20

8.64 ± 2.83

8.68 ± 3.23

0.661

Uric acid (mg/dl)

7.15 ± 1.63

7.03 ± 1.60

7.17 ± 1.64

7.07 ± 1.62

7.32 ± 1.66

0.009*

Urea nitrogen (mg/dl)

49.8 ± 29.2

50.7 ± 21.0

49.2 ± 20.4

50.6 ± 20.2

48.9 ± 19.2

0.240

eGFR (ml/min/1.73 m2)

6.73 ± 2.84

6.75 ± 2.71

6.73 ± 2.87

6.70 ± 2.65

6.73 ± 3.12

0.926

hs-CRP (mg/l)

1.69 (0.66–5.31)

0.86 (0.36–2.78)

1.25 (0.24–3.95)

1.58 (0.57–4.84)

2.92 (1.03–7.43)

< 0.001*

Medicine

      

Antihypertension agents, n (%)

2010 (86.1)

483 (82.7)

498 (85.3)

509 (87.2)

520 (89.2)

0.041*

Antidiabetics agents, n (%)

331 (14.2)

23 (3.9)

48 (8.2)

96 (16.4)

164 (28.1)

< 0.001*

Lipid-lowering agents, n (%)

251 (10.7)

29 (5.0)

46 (7.9)

70 (12.0)

106 (18.2)

< 0.001*

  1. BMI body mass index, CVD cardiovascular disease, FBG fasting blood glucose, TyG triglyceride glucose, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, eGFR estimated glomerular filtration rate, hs-CRP high-sensitivity C-reactive protein